SOPHiA GENETICS Muken proposes $3.46K share sale

The reported Rule 10b5-1 plan adoption date for director and officer Ross J. Muken is August 26, 2025.

Available on EDGAR 09/21/2026 - 04:28 PM EDT Accepted by SEC EDGAR 09/21/2026 - 04:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SOPHiA GENETICS SA director and officer Ross J. Muken reported a proposed sale of 422 common shares, with an approximate sale date of September 21, 2026, and an aggregate market value of $3,456.18. The shares were acquired from the issuer as restricted stock units on September 18, 2026. The proposed sale is reported in connection with a Rule 10b5-1 plan adopted August 26, 2025.

Muken also reported earlier Rule 10b5-1 sales: 9,838 shares for gross proceeds of $51,354.36 on July 6, 2026, and 422 shares for gross proceeds of $2,270.49 on June 22, 2026.

Key Figures

Proposed sale: 422 common shares Aggregate market value: $3,456.18 Shares outstanding: 85,127,825 shares +4 more

7 metrics

Proposed sale 422 common shares Approximate sale date September 21, 2026

Aggregate market value $3,456.18 Proposed sale of 422 common shares

Shares outstanding 85,127,825 shares Issuer share count listed in the securities information

Earlier sale 9,838 shares July 6, 2026; Rule 10b5-1 sales

Gross proceeds $51,354.36 Earlier sale on July 6, 2026

Earlier sale 422 shares June 22, 2026; Rule 10b5-1 sales

Gross proceeds $2,270.49 Earlier sale on June 22, 2026

Key Terms

Rule 10b5-1, Restricted Stock Units, Aggregate Market Value, Gross Proceeds

4 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption ... If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Restricted Stock Units financial

"Nature of Acquisition Transaction: Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does SOPH director and officer Ross J. Muken propose to sell?

Ross J. Muken reported a proposed sale of 422 common shares, with an approximate sale date of September 21, 2026, and an aggregate market value of $3,456.18.

When was SOPH director and officer Ross J. Muken's Rule 10b5-1 plan adopted?

The reported plan adoption date is August 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002005463
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SOPHIA GENETICS SA
SEC File Number	001-40627
Address of Issuer	La Piece 12 ch-1180 Rolle SWITZERLAND 00000
Phone	41216941060
Name of Person for Whose Account the Securities are To Be Sold	ROSS J MUKEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	422	3456.18	85127825	09/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/18/2026	Restricted Stock Units	Issuer			422	09/18/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	07/06/2026	9838	51354.36
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	06/22/2026	422	2270.49

144: Remarks and Signature

Remarks
Date of Notice	09/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ross J Muken
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)